176 related articles for article (PubMed ID: 37962616)
1. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
Piccardo A; Treglia G; Fiz F; Bar-Sever Z; Bottoni G; Biassoni L; Borgwardt L; de Keizer B; Jehanno N; Lopci E; Kurch L; Massollo M; Nadel H; Roca Bielsa I; Shulkin B; Vali R; De Palma D; Cecchin D; Santos AI; Zucchetta P
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):756-767. PubMed ID: 37962616
[TBL] [Abstract][Full Text] [Related]
2. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.
Piccardo A; Lopci E; Conte M; Garaventa A; Foppiani L; Altrinetti V; Nanni C; Bianchi P; Cistaro A; Sorrentino S; Cabria M; Pession A; Puntoni M; Villavecchia G; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):57-71. PubMed ID: 21932116
[TBL] [Abstract][Full Text] [Related]
4. [
Wang P; Li T; Liu Z; Jin M; Su Y; Zhang J; Jing H; Zhuang H; Li F
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3097-3106. PubMed ID: 37160439
[TBL] [Abstract][Full Text] [Related]
5. [
Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
[TBL] [Abstract][Full Text] [Related]
6. Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.
Zhang H; Huang R; Cheung NK; Guo H; Zanzonico PB; Thaler HT; Lewis JS; Blasberg RG
Clin Cancer Res; 2014 Apr; 20(8):2182-91. PubMed ID: 24573553
[TBL] [Abstract][Full Text] [Related]
7. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis, Treatment Response, and Prognosis: The Role of
Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma.
Piccardo A; Puntoni M; Lopci E; Conte M; Foppiani L; Sorrentino S; Morana G; Naseri M; Cistaro A; Villavecchia G; Fanti S; Garaventa A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1046-56. PubMed ID: 24562643
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
12. [
Pauwels E; Celen S; Baete K; Koole M; Bechter O; Bex M; Renard M; Clement PM; Jentjens S; Serdons K; Van Laere K; Bormans G; Deroose CM
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1134-1145. PubMed ID: 36435928
[TBL] [Abstract][Full Text] [Related]
13.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
16. Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.
Xia J; Zhang H; Hu Q; Liu SY; Zhang LQ; Zhang A; Zhang XL; Wang YQ; Liu AG
J Huazhong Univ Sci Technolog Med Sci; 2017 Oct; 37(5):649-660. PubMed ID: 29058276
[TBL] [Abstract][Full Text] [Related]
17. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.
Cistaro A; Quartuccio N; Caobelli F; Piccardo A; Paratore R; Coppolino P; Sperandeo A; Arnone G; Ficola U
Nucl Med Rev Cent East Eur; 2015; 18(2):102-6. PubMed ID: 26315872
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
19. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
20. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.
Franzius C; Hermann K; Weckesser M; Kopka K; Juergens KU; Vormoor J; Schober O
J Nucl Med; 2006 Oct; 47(10):1635-42. PubMed ID: 17015899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
